Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 32

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling

Asp, Michelle L., Martindale, Joshua J., Metzger, Joseph M. · 2013 · PLoS ONE

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0078768

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 42

  1. A Umar, 2012, Future directions in cancer prevention, Nat Rev Cancer, 12, 835, 10.1038/nrc3397 · DOI · Paper page
  2. A Michalski, 2010, The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma, J Neuro Oncol, 100, 81, 10.1007/s11060-010-0141-9 · doi:10.1007/s11060-010-0141-9
  3. P Tang, 2006, A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma, J Neuro Oncol, 78, 311, 10.1007/s11060-005-9104-y · DOI
  4. IF Pollack, 1997, A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood, Clin Cancer Res, 3, 1109
  5. S Patel, 2012, Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma, Int J Radiat Oncol Biol Phys, 82, 739, 10.1016/j.ijrobp.2010.12.053 · doi:10.1016/j.ijrobp.2010.12.053
  6. NS Stuart, 1992, High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines, Br J Cancer, 66, 833, 10.1038/bjc.1992.369 · DOI
  7. DL Trump, 1992, High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine, J Natl Cancer Inst, 84, 1811, 10.1093/jnci/84.23.1811 · DOI · Paper page
  8. CA O'Brian, 1985, Inhibition of protein kinase C by tamoxifen, Cancer Res, 45, 2462
  9. E Berman, 1991, Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype, Blood, 77, 818, 10.1182/blood.V77.4.818.818 · doi:10.1182/blood.v77.4.818.818
  10. L Slovacek, 2008, Tamoxifen-induced QT interval prolongation, J Clin Pharm Ther, 33, 453, 10.1111/j.1365-2710.2008.00928.x · doi:10.1111/j.1365-2710.2008.00928.x
  11. S Beca, 2008, Inhibition of a cardiac sarcoplasmic reticulum chloride channel by tamoxifen, Pflugers Arch, 457, 121, 10.1007/s00424-008-0510-9 · DOI
  12. D Ponce-Balbuena, 2009, Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions, J Pharmacol Exp Ther, 331, 563, 10.1124/jpet.109.156075 · DOI
  13. D Ponce-Balbuena, 2010, Tamoxifen inhibits cardiac ATP-sensitive and acetylcholine-activated K+ currents in part by interfering with phosphatidylinositol 4,5-bisphosphate-channel interaction, J Pharmacol Sci, 113, 66, 10.1254/jphs.10024FP · DOI
  14. V Vasioukhin, 1999, The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proc Natl Acad Sci U S A, 96, 8551, 10.1073/pnas.96.15.8551 · DOI · Paper page
  15. JJ McCarthy, 2012, Inducible Cre transgenic mouse strain for skeletal muscle-specific gene targeting, Skelet Muscle, 2, 8, 10.1186/2044-5040-2-8 · DOI · Paper page
  16. ME Gómez-Casati, 2010, Cell-specific inducible gene recombination in postnatal inner ear supporting cells and glia, J Assoc Res Otolaryngol, 11, 19, 10.1007/s10162-009-0191-x · DOI
  17. DS Sohal, 2001, Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein, Circ Res, 89, 20, 10.1161/hh1301.092687 · DOI · Paper page
  18. TD Littlewood, 1995, A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins, Nucleic Acids Res, 23, 1686, 10.1093/nar/23.10.1686 · DOI · Paper page
  19. Y Zhang, 1996, Inducible site-directed recombination in mouse embryonic stem cells, Nucleic Acids Res, 24, 543, 10.1093/nar/24.4.543 · DOI · Paper page
  20. PS Danielian, 1993, Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen, Mol Endocrinol, 7, 232
  21. WB Pratt, 1990, Interaction of hsp90 with steroid receptors: organizing some diverse observations and presenting the newest concepts, Mol Cell Endocrinol, 74, C69, 10.1016/0303-7207(90)90198-H · DOI
  22. J Davis, 2012, Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research, Circ Res, 111, 761, 10.1161/CIRCRESAHA.111.262717 · DOI
  23. A Buerger, 2006, Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase, J Card Fail, 12, 392, 10.1016/j.cardfail.2006.03.002 · DOI
  24. N Koitabashi, 2009, Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models, Circ Res, 105, 12, 10.1161/CIRCRESAHA.109.198416 · DOI · Paper page
  25. K Hougen, 2010, Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice, Am J Physiol Heart Circ Physiol, 299, H1671, 10.1152/ajpheart.01155.2009 · DOI
  26. GM Kravtsov, 2007, Altered Ca(2+) handling by ryanodine receptor and Na(+)-Ca(2+) exchange in the heart from ovariectomized rats: role of protein kinase A, Am J Physiol Cell Physiol, 292, C1625, 10.1152/ajpcell.00368.2006 · DOI
  27. E Filice, 2011, Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart, Cell Physiol Biochem, 28, 41, 10.1159/000331712 · DOI
  28. J Kulpa, 2012, Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha, PLOS ONE, 7, e41076, 10.1371/journal.pone.0041076 · DOI
  29. W Wang, 2013, Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance, Nat Med, 19, 305, 10.1038/nm.3079 · DOI · Paper page
  30. K Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, J Clin Oncol, 28, 2768, 10.1200/JCO.2009.23.8931 · DOI
  31. BS Katzenellenbogen, 1984, Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells, Cancer Res, 44, 112
  32. E Filice, 2009, A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat, J Physiol Pharmacol, 60, 3
  33. J Duan, 2004, Comparison of cardiac contractile and intracellular Ca2+ response between estrogen and phytoestrogen alpha-zearalanol in ventricular myocytes, Endocrine, 24, 33, 10.1385/ENDO:24:1:033 · doi:10.1385/endo:24:1:033
  34. J He, 2003, Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes, Am J Physiol Heart Circ Physiol, 285, H661, 10.1152/ajpheart.00686.2002 · DOI
  35. J Song, 1996, Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats, J Pharmacol Exp Ther, 277, 1444
  36. ND Ullrich, 2008, Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes, Am J Physiol Heart Circ Physiol, 294, H2421, 10.1152/ajpheart.01225.2007 · DOI
  37. ME Kargacin, 2000, Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum, Pflugers Arch, 440, 573, 10.1007/s004240000318 · DOI
  38. L Xie, 2007, In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators, PLOS Comput Biol, 3, e217, 10.1371/journal.pcbi.0030217 · DOI
  39. R Liew, 2004, Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current, Br J Pharmacol, 142, 89, 10.1038/sj.bjp.0705736 · DOI
  40. B Lewartowski, 1990, Net Ca2+ influx and sarcoplasmic reticulum Ca2+ uptake in resting single myocytes of the rat heart: comparison with guinea-pig, J Mol Cell Cardiol, 22, 1221, 10.1016/0022-2828(90)90059-B · DOI
  41. M Furlanut, 2007, Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women, Ther Drug Monit, 29, 349, 10.1097/FTD.0b013e318067ded7 · doi:10.1097/ftd.0b013e318067ded7
  42. ER Kisanga, 2003, Tamoxifen administration and metabolism in nude mice and nude rats, J Steroid Biochem Mol Biol, 84, 361, 10.1016/S0960-0760(03)00051-7 · DOI

Cited by

See all 32

Metadata

Authors
Asp, M. L., Martindale, J. J., & Metzger, J. M.
Venue
PLoS ONE
Published
2013-10-24
Volume
8
Issue
10
Pages
e78768
ISSN
1932-6203
Cited by
32
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling. https://app.cochat.ai/papers/10.1371/journal.pone.0078768
The paper
Asp, M. L., Martindale, J. J., & Metzger, J. M. (2013). Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling. PLoS ONE. https://doi.org/10.1371/journal.pone.0078768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.